Nimbus Apollo is a program under Nimbus Therapeutics that focuses on the development of innovative treatments for serious diseases, particularly targeting non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). The program's lead candidate, NDI-010976, is an allosteric inhibitor of Acetyl-CoA Carboxylase (ACC), which has received Fast Track designation from the U.S. Food and Drug Administration. Nimbus Apollo is engaged in advancing this candidate through various stages of clinical development, with Phase 1 data expected to be presented at notable medical conferences. Nimbus Therapeutics, founded in 2009 and based in Cambridge, Massachusetts, leverages computational technology to design selective and potent small molecule therapeutics aimed at addressing metabolic diseases, cancer, and immune-inflammatory disorders. The company has established strategic partnerships to enhance its research and development efforts.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
Hometap Equity Partners, LLC provides near-immediate access to funds to homeowners for the things they need and want without having to incur further debt through a home equity loan or second mortgage. The company provides home equity investments with no set credit score, no interest rates, and no monthly payments to change the face of homeownership and provide financial stability to homeowners. It also develops a data-driven home equity investment platform to extend its initiatives to educate homeowners. The company was founded in 2017 and is based in Boston, Massachusetts.
Cardurion Pharmaceuticals, LLC operates as a biotechnology company. The company was incorporated in 2017 and is based in Boston, Massachusetts.
Private Equity Round in 2021
ConvenientMD Urgent Care offers convenient access to high-quality medical care, at the most affordable rates around. Patients can just walk in, without making an appointment, from 8 am to 8 pm, seven days a week. Patients are typically in and out in under 1 hour and there is always a full medical team on site. The center has friendly staff who provide world-class customer service with state-of-the-art medical equipment, including digital x-ray, lab, EKG, and IV equipment. ConvenientMD’s expert medical team is ready and equipped to treat a broad range of injuries and illness.
ConvenientMD has NH locations in Bedford, Concord, Dover, Exeter, Keene, Merrimack, Nashua, Portsmouth, and Windham. Maine locations include Westbrook and Portland, with additional locations opening throughout New England.
Cerevel (www.cerevel.com) is a biopharmaceutical company focused on developing drug candidates to treat disorders of the central nervous system (CNS). The company has a portfolio of pre-commercial neuroscience assets, which include three clinical-stage compounds and several pre-clinical compounds designed to target a broad range of CNS disorders including Parkinson’s, Alzheimer’s, epilepsy, schizophrenia and addiction. Headquartered in the Greater Boston area, Cerevel was formed in 2018 through a partnership between Bain Capital and Pfizer.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutics for primary immune deficiencies and cancer. The company's lead drug candidate, mavorixafor, is an oral small molecule antagonist of the CXCR4 chemokine receptor, currently undergoing various clinical trials. Mavorixafor is in Phase III trials for treating patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome, and is also being tested in Phase Ib trials for severe congenital neutropenia and Waldenström macroglobulinemia, alongside a Phase IIa trial for clear cell renal cell carcinoma. Additionally, X4 Pharmaceuticals is advancing X4P-002, aimed at treating glioblastoma multiforme, and is developing X4P-003 for primary immune deficiencies. The company has established a license agreement with Abbisko Therapeutics to explore the use of mavorixafor in combination with checkpoint inhibitors for oncology applications. Founded in 2014, X4 Pharmaceuticals was previously known as Arsanis, Inc. before rebranding in March 2019.
Xilio Therapeutics is a biotechnology company advancing next-generation cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. The company’s tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects. The broad applicability of these therapies across cancer types means that all patients could benefit from these potentially curative medicines. These tumor-selective therapies are designed to overcome the significant toxicities associated with validated IO therapies, such as IL-2 and aCTLA4, which have historically limited the number of patients that can be treated and prevented patients from completing full courses of treatment Xilio Therapeutics proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. The company applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, Massachusetts, United States.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Syros Pharmaceuticals is a biopharmaceutical company dedicated to developing treatments for cancer and genetic disorders through innovative gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing a Phase II clinical trial for specific patient subsets with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in a Phase I clinical trial for select advanced solid tumors. Syros employs a unique approach that integrates gene regulatory circuit mapping and modulation of gene expression factors, supported by a proprietary platform of assay technologies and bioinformatics. The company collaborates with Incyte Corporation to discover therapeutic targets, particularly for myeloproliferative neoplasms, and has a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. Founded in 2011 and headquartered in Cambridge, Massachusetts, Syros Pharmaceuticals was previously known as LS22, Inc. and rebranded in 2012.
AavantiBio, Inc. engages in developing gene transfer therapy and gene editing technologies to improve the lives of people living with fatal diseases. It focuses on Friedreich’s Ataxia (FA), a rare inherited genetic disease that causes cardiac and central nervous system dysfunction. The company was incorporated in 2019 and is based in Gainesville, Florida.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
Affinivax, Inc. is a biotechnology company based in Lexington, Massachusetts, that specializes in developing vaccines using its innovative Multiple Antigen Presenting System (MAPS) technology. This approach allows for the combination of protective polysaccharides and proteins in a single vaccine, aiming to enhance the immune response against various infectious diseases. Affinivax focuses on a range of pathogens, including Streptococcus pneumoniae, which poses significant health risks to both children and adults. The company seeks to create vaccines that provide broader disease coverage and address infectious diseases lacking effective immunization strategies. Founded in 2014, Affinivax benefits from insights provided by leading experts in infectious diseases and vaccines, and it has secured support from the Bill & Melinda Gates Foundation, along with exclusive licensing rights from Boston Children’s Hospital for its MAPS technology.
Mersana Therapeutics employs its biodegradable polymer platform to create new and better medicines. They are advancing their own clinical-stage pipeline of novel compounds with the potential to address multiple oncology indications.
It was founded in 2005 and headquartered in Cambridge, Massachusetts.
EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.
The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.
The company was founded in 2003 and is based in Branford, Connecticut.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing therapeutics aimed at addressing significant unmet medical needs in cancer treatment, particularly those related to abnormal gene expression and drug resistance. The company's lead product candidates include CPI-0610, currently undergoing Phase II clinical trials for myelofibrosis in combination with ruxolitinib, and CPI-1205, which is in Phase Ib/II trials for metastatic castration-resistant prostate cancer alongside androgen receptor signaling inhibitors. Additionally, Constellation is developing CPI-0209, which is in the dose escalation phase of a Phase I/II clinical trial for solid tumors. Founded in 2008, the company was previously known as Epigenetix, Inc. and has established itself as a pioneer in the emerging field of epigenetics, which focuses on selective regulators of epigenetic function crucial for gene expression control.
SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.
The company was founded in 2017 and headquartered in Connecticut, United States.
HealthDrive was founded in 1989 by medical professionals who saw the need for a higher level of on-site medical and dental services in long-term care facilities. Their founders began assembling specialty doctors, skilled providers and practitioners who were rated to be the best in their field. Since then, HealthDrive has grown to employ 120 medical and dental providers in over 1,000 facilities, serving more than 135,000 senior living residents around the nation. They understand the critical importance of good health and how it leads to a better quality of life. Their highly skilled on-site medical service providers not only deliver proactive healthcare to seniors in long-term care facilities, but deliver those services with the utmost care and empathy. HealthDrive provides long-term care residents with dental, optometry, podiatry and audiology services where they reside, bringing services to senior living facilities who partner with us. Learn more about what makes us a leading provider:
Rocket Software, Inc. develops and supports enterprise software solutions that cater to a diverse range of industries, including automotive, healthcare, finance, and technology. Founded in 1990 and headquartered in Waltham, Massachusetts, the company provides products in various domains such as application lifecycle management, data management, business intelligence, and modernization. Rocket Software also offers training, consulting, and professional services to enhance its software solutions. The company has a global presence with offices in North America, Europe, and Asia, and it serves clients that include hardware and software vendors, OEMs, and various sectors seeking to improve their operational efficiencies and data management capabilities.
Rapid Micro Biosystems provides products for the detection of microbial contamination in the manufacture of pharmaceutical, biotechnology, and personal care products. It offers the Growth Direct System, a non-destructive method for microbial enumeration.
The company was formerly known as Genomic Profiling Systems and changed its name to Rapid Micro Biosystems in 2007. Rapid Micro Biosystems was founded in 2006 and is based in Bedford, Massachusetts.
SpringWorks Therapeutics is a biotechnology company that specializes in identifying, developing, and commercializing therapies for underserved patient populations suffering from severe rare diseases and cancer. The firm's pipeline product includes Mirdametinib, Nirogacestat, and others.
The company was founded in 2017 and headquartered in Connecticut, United States.
Marinus Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of ganaxolone, offering a new mechanism of action with safe and convenient dosing, for adult and pediatric patient populations in acute and chronic care settings.
The company was founded in 2003 and is based in Branford, Connecticut.
Replimune Group, Inc., a biotechnology company, develops oncolytic immune-gene therapies to treat cancer. It uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Private Equity Round in 2017
Impact Fitness is a leading Planet Fitness franchisee with 29 clubs across the United States and Canada. Here At Impact Fitness, We Believe In Revolutionizing The Fitness Industry. Our Gym Is A Strong, Safe, Exciting And Positive Atmosphere For Everyone. We Offer Only The Most Innovated State Of The Art Equipment, The Biggest Selection Of Free Weights, The Newest In Technology For Cardio Training And The Best In Class Group Exercise Program With An Unparalleled Level Of Commitment To Our Gym Members To Help Them Succeed In Their Fitness Goals. Impact Fitness Is A Gym For Everyone To Come And Achieve The Best They Can From Themselves, No Matter What Your Goal Is. Come See Why Our Local Gym in Auburn Is Making A Difference In How Everyone Achieves Their Fitness Goals Today!
Solid Biosciences Inc. is a life science company focused on developing therapies for Duchenne muscular dystrophy (DMD), a severe genetic disorder primarily affecting boys. The company's lead candidate, SGT-001, is a gene transfer therapy currently undergoing a Phase I/II clinical trial aimed at restoring functional dystrophin protein expression in muscle tissues. In addition to SGT-001, Solid Biosciences is advancing Anti-LTBP4, a monoclonal antibody designed to mitigate fibrosis and inflammation by targeting the LTBP4 protein. The company also works on developing biomarkers and wearable assistive devices under the Solid Suit program, which aims to provide therapeutic benefits to patients. Founded in 2013 and headquartered in Cambridge, Massachusetts, Solid Biosciences has established a strategic collaboration with Ultragenyx to further develop and commercialize gene therapies for DMD. The company’s initiatives address a critical need, as there are currently no effective cures or satisfactory treatments for this progressive and life-threatening condition.
Dicerna Pharmaceuticals is a biotechnology company involved in the discovery and development of innovative treatments for rare inherited diseases affecting the liver, along with cancers, and other therapeutic areas to address liver problems. It is using ribonucleic acid interference (RNA) technology platform to develop its products. The product candidates are DCR-PHXC (for primary hyperoxaluria), DCR-undisclosed (for orphan genetic disease), DCR-PCSK9 (for cardiovascular disease), and DCR-HBV (for hepatitis B virus) among others.
The company was founded in 2007 and is headquartered in Lexington, Massachusetts.
Daymon Worldwide, Inc. is a leading provider of consumables retailing services, specializing in the branding and commercialization of customized retail solutions. Founded in 1970 and based in Stamford, Connecticut, the company offers a comprehensive range of services, including private brand development, category analytics, product sourcing, and supplier management. Daymon also provides strategy and branding services such as brand identity design, shopper marketing, and digital engagement. Additionally, it focuses on sourcing and logistics, encompassing supply chain optimization and global distribution. The company delivers retail services that include store remodeling, audits, and display assembly. Furthermore, Daymon engages in consumer experience marketing through in-store product sampling and other promotional activities. It serves a diverse clientele across various retail channels, including convenience stores, drug stores, e-commerce platforms, and supercenters, leveraging its extensive network of associates to provide tailored solutions that enhance sales and market presence.
Turbonomic specializes in Application Resource Management, focusing on optimizing the performance of applications by aligning their demand with available infrastructure resources. The company's software operates across on-premises and multicloud environments, facilitating real-time workload automation that enhances performance, reduces costs, and ensures compliance. By integrating with prominent Application Performance Management (APM) and IT service management tools, Turbonomic creates a comprehensive control plane for automating IT resource management, thereby streamlining operations and improving efficiency for organizations managing complex IT landscapes.
Provides infrastructure performance monitoring solutions for customers worldwide
Invoke Solutions offers real-time online research services that offer fast, usable insights for their clients. Invoke Solutions products are used by companies including Microsoft, Washington Mutual, Conagra, Dell, erBay, Verizon, and Nestle to conduct better, faster, brand, communications, and product research in the US and globally.
Their Engage online and mobile applications enable clients and partners to blend qualitative and quantitative real-time research.
(Source: [Invoke Solutions](http://www.invoke.com))
GameLogic innovates games, promotions and marketing interfaces to help casino operators communicate and interact with their customers when they are away from the casino, ultimately establishing deeper bonds of player loyalty leading to increased casino visitation.
CentrePath, Inc. is a provider of intelligent management solutions for optical and storage networks, previously known as GiantLoop Network. The company specializes in helping organizations build and manage these networks, focusing on improving service availability while minimizing management costs. CentrePath's solutions are designed for mission-critical environments, ensuring business continuity and supporting the convergence of voice, video, and data. The company markets its data center networking solutions to various industries, including healthcare, financial services, media, and entertainment. Their services encompass critical networking functions such as event correlation, root cause identification, impact analysis, and performance monitoring. This enables clients to effectively conduct network staging, certification, space design, fiber testing, project management, and network transport services.
ProfitLogic engages in the development and marketing of retail profit optimization software solutions. It offers retail profit optimization, price optimization, and inventory planning software solutions for all retail verticals, which include assortment and allocation, pricing, in-season inventory management, promotions and marketing, and performance assessment and management solutions. The company provides applications to help retailers make profitable allocation, planning, and pricing decisions; and a marketer of profit optimizations systems. ProfitLogic, Inc. was formerly known as Technology Strategy, Inc. (TSI). The company was founded in 1983 and is based in Cambridge, Massachusetts.
deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.
ProfitLogic engages in the development and marketing of retail profit optimization software solutions. It offers retail profit optimization, price optimization, and inventory planning software solutions for all retail verticals, which include assortment and allocation, pricing, in-season inventory management, promotions and marketing, and performance assessment and management solutions. The company provides applications to help retailers make profitable allocation, planning, and pricing decisions; and a marketer of profit optimizations systems. ProfitLogic, Inc. was formerly known as Technology Strategy, Inc. (TSI). The company was founded in 1983 and is based in Cambridge, Massachusetts.
deNovis Inc. is a leading provider of advanced transaction processing and information management solutions for the health insurance and health care benefits administration industry. deNovis's highly innovative claims processing and data management software enables commercial and government health plans to reduce administrative costs, expand their range of products and services, increase speed-to-market of new products and enhance the quality of customer service. The company's flagship software product—eHD™—serves as the core administrative platform for health plans and is designed to deliver the sophistication necessary to meet both existing and emerging needs of commercial, Medicare and Medicaid healthcare benefits administrators. deNovis is also known for its technical innovations, including HICL™ technology, which allows complex healthcare transaction systems to be programmed by business analysts rather than computer programmers, using English language commands and the actual policies and business rules of the health plan. deNovis's customer roster includes large commercial insurers and the U. S. Department of Health and Human Services—the nation's largest purchaser of healthcare and a provider of healthcare benefits to almost 80 million Americans. The company's strategic alliance partners include IBM Corporation and Deloitte Consulting. deNovis enterprise solutions for health plans are available for installation at customer locations or can be delivered on an outsourced or remote-hosted basis. The company is privately held and is headquartered in Lexington, Massachusetts.
Solect Technology Group is a computer software company that provides IP billing and customer care software. The company is based in Madrid, Spain.